A multicenter, phase II, randomized, noncomparative clinical trial of radiation and temozolomide with or without vandetanib in newly diagnosed glioblastoma patients Academic Article uri icon

Overview

MeSH Major

  • Dacarbazine
  • Glioblastoma
  • Piperidines
  • Quinazolines

abstract

  • The addition of vandetanib at a dose of 100 mg daily to standard chemoradiation in patients with newly diagnosed GBM or gliosarcoma was associated with potential pharmacodynamic biomarker changes and was reasonably well tolerated. However, the regimen did not significantly prolong OS compared with the parallel control arm, leading to early termination of the study.

publication date

  • August 15, 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4790106

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-14-3220

PubMed ID

  • 25910950

Additional Document Info

start page

  • 3610

end page

  • 8

volume

  • 21

number

  • 16